High-Performance CRISPR-Cas9 Engineered for Superior Therapeutic Gene Editing

Patent Status

Brief Description

Efficient delivery and genome editing remain critical challenges in advancing CRISPR-based cell and gene therapies. Therapeutic applications, particularly ex vivo cell therapies, require highly active CRISPR systems capable of achieving robust editing with low, transient ribonucleoprotein (RNP) dosing to maximize efficacy while minimizing manufacturing costs and potential safety concerns.

Researchers at UC Berkeley have developed a next-generation CRISPR-Cas9 platform that significantly enhances genome editing performance through strategically engineered nuclear localization signals (NLSs). Rather than relying on conventional terminal NLS fusions, which can reduce protein expression and manufacturing yield when used in multiple copies, this innovation incorporates multiple NLS sequences at carefully selected internal positions within the Cas9 protein.

The resulting Cas9 variants deliver substantially improved editing efficiency in human T cells while maintaining high protein purity and manufacturing yields, overcoming a key tradeoff that has limited previous CRISPR engineering approaches.

This technology offers a compelling advantage for developers of cell and gene therapies by enabling:

• Higher genome editing efficiency at lower RNP doses
• Improved performance in ex vivo therapeutic workflows, including T-cell engineering
• High-yield, scalable protein manufacturing compatible with commercial production
• A differentiated Cas9 platform that can enhance the performance of existing CRISPR-based therapeutics

With its combination of enhanced biological activity and manufacturability, this engineered Cas9 platform has broad commercial potential across cell therapy, gene editing, and genome engineering applications.